1. Home
  2. XMTR vs GENB Comparison

XMTR vs GENB Comparison

Compare XMTR & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xometry Inc.

XMTR

Xometry Inc.

HOLD

Current Price

$39.96

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

GENB

Generate Biomedicines Inc. Common Stock

N/A

Current Price

$11.46

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
XMTR
GENB
Founded
2013
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.7B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
XMTR
GENB
Price
$39.96
$11.46
Analyst Decision
Buy
Strong Buy
Analyst Count
10
5
Target Price
$58.60
$25.00
AVG Volume (30 Days)
814.2K
364.6K
Earning Date
05-05-2026
05-03-2026
Dividend Yield
N/A
N/A
EPS Growth
26.95
N/A
EPS
N/A
N/A
Revenue
$686,631,000.00
N/A
Revenue This Year
$23.76
N/A
Revenue Next Year
$18.38
$45.45
P/E Ratio
N/A
N/A
Revenue Growth
25.87
N/A
52 Week Low
$20.95
$11.00
52 Week High
$73.87
$14.21

Technical Indicators

Market Signals
Indicator
XMTR
GENB
Relative Strength Index (RSI) 43.26 44.08
Support Level $39.50 $11.21
Resistance Level $42.98 $13.69
Average True Range (ATR) 2.59 1.12
MACD 0.67 -0.10
Stochastic Oscillator 30.94 9.65

Price Performance

Historical Comparison
XMTR
GENB

About XMTR Xometry Inc.

Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.

About GENB Generate Biomedicines Inc. Common Stock

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Share on Social Networks: